Gujarat Themis Biosyn Limited (BOM:506879)

Market Cap	34.39B
Revenue (ttm)	1.55B
Net Income (ttm)	482.95M
Shares Out	108.97M
EPS (ttm)	4.44
PE Ratio	71.16
Forward PE	n/a
Dividend	0.67 (0.20%)
Ex-Dividend Date	Sep 4, 2025

Volume	33,727
Average Volume	16,402
Open	355.55
Previous Close	360.60
Day's Range	330.65 - 355.55
52-Week Range	192.35 - 479.45
Beta	-0.30
RSI	34.32
Earnings Date	Feb 14, 2026

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 221
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506879

Financial Performance

In 2024, Gujarat Themis Biosyn's revenue was 1.51 billion, a decrease of -11.20% compared to the previous year's 1.70 billion. Earnings were 487.72 million, a decrease of -17.56%.